All In Biotech

Drug Trial Radar · NCT02952820

Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder (SUNRISE 2)

Last checked: Nov 20, 2026Latest source record: Feb 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 971 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

971

Actual

Start

Nov 15, 2016

Primary completion

Jan 8, 2019

Study completion Jan 8, 2019

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Nov 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.

Conditions

  • Insomnia Disorder

Interventions

  • lemborexantDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6Time frame: Baseline and Month 6

Locations

114 sites in 12 countries. Site status is shown where the registry gives one.

  • Facility # 1

    Chandler, Arizona

  • Facility # 2

    Chandler, Arizona

  • Facility # 1

    Rogers, Arkansas

  • Facility # 1

    Beverly Hills, California

  • Facility # 2

    Los Angeles, California

  • Facility # 1

    Los Angeles, California

  • Facility # 1

    Redlands, California

  • Facility # 1

    Sacramento, California

  • Facility # 1

    Santa Monica, California

  • Facility # 1

    Torrance, California

  • Facility # 1

    Colorado Springs, Colorado

  • Facility # 1

    Celebration, Florida

  • Facility # 1

    Hialeah, Florida

  • Facility # 1

    Homestead, Florida

  • Facility # 1

    Jacksonville, Florida

  • Facility # 1

    Lauderhill, Florida

  • Facility # 1

    Maitland, Florida

  • Innovative Clinical Research Inc

    Miami, Florida

  • Facility # 1

    Ocala, Florida

  • Facility # 1

    Orlando, Florida

  • Facility # 1

    Oviedo, Florida

  • Facility # 1

    Pinellas Park, Florida

  • Facility # 1

    Tampa, Florida

  • Facility # 1

    The Villages, Florida

  • Facility # 1

    Evansville, Indiana

  • Facility # 1

    Elkridge, Maryland

  • Facility # 1

    Quincy, Massachusetts

  • Facility # 1

    Kansas City, Missouri

  • Facility # 1

    Albuquerque, New Mexico

  • Facility # 1

    Brooklyn, New York

  • Facility # 1

    Hickory, North Carolina

  • Facility # 1

    Dayton, Ohio

  • Facility # 2

    Oklahoma City, Oklahoma

  • Facility # 1

    Oklahoma City, Oklahoma

  • Facility # 1

    Portland, Oregon

  • Facility # 1

    Lincoln, Rhode Island

  • Facility # 1

    Memphis, Tennessee

  • Facility # 1

    Austin, Texas

  • Facility # 2

    Austin, Texas

  • Facility # 1

    Fort Worth, Texas

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.